Production (Stage)
LENZ Therapeutics, Inc.
LENZ
$31.96
$1.665.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.19% | 46.60% | 45.90% | 30.37% | -31.40% |
| Total Depreciation and Amortization | 620.00% | 525.00% | 150.00% | 350.00% | 66.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.57% | 184.73% | 1,039.73% | 228.87% | 987.97% |
| Change in Net Operating Assets | 67.06% | 11.64% | -121.14% | -717.23% | -3,018.69% |
| Cash from Operations | 32.95% | 56.71% | 19.15% | -16.79% | -87.04% |
| Capital Expenditure | -- | -- | -- | -454.17% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.55% | -177.20% | -246.34% | -265.93% | -- |
| Cash from Investing | 4.94% | -178.18% | -247.38% | -266.10% | 300,100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.92% | -- | -- | -- | 26,410.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 97.71% | -- | -- |
| Cash from Financing | -99.97% | 102.77% | 5,349.65% | -- | 105.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.26% | -170.99% | -36.17% | -187.93% | 134.93% |